Melissa G. Ooi

TL;DR: These studies demonstrate a novel mechanism of action for lenalidomide, namely targeting SP fraction, providing the framework for new therapeutic strategies targeting subpopulations of MM cells including presumptive stem cells.

TL;DR: BEZ235 treatment decreased the amplitude of transcriptional signatures previously associated with myc, ribosome, and proteasome function, as well as high-risk MM and undifferentiated human embryonic stem cells, and indicates that BEZ235 merits clinical testing, alone and in combination with other agents, in multiple myeloma.

TL;DR: Sulforaphane and phenylethyl isothiocyanate enhanced the in vitro anti-myeloma activity of several conventional and novel therapies used in multiple myelomas and may enhance the activity of other anti-multiple myeloma agents.

TL;DR: Conurrent Hdm2 inhibition with bortezomib may extend the spectrum of bortrazomib applications to malignancies with currently limited sensitivity to single-agent bortzomib or, in the future, to MM patients with decreased clinical responsiveness to bortazomib-based therapy.

TL;DR: It is shown that bortezomib is a substrate for P-gp, but not for the other drug efflux transporters, and that combination of a P-GP inhibitor and bortzomib in P- gp positive myeloma would be a reasonable treatment combination to extend efficacy of this important drug.